Document is current
Any future updates will be listed below
-
Authors
Ghoreishi, Maryamsadat https://orcid.org/0000-0002-1923-1488
Senturk, Efsun
Cidonio, Gianluca https://orcid.org/0000-0002-9445-6994
Scognamiglio, Chiara https://orcid.org/0000-0001-9616-4277
Salajková, Zita https://orcid.org/0000-0001-5085-9698
Riminucci, Mara https://orcid.org/0000-0002-8643-9211
Corsi, Alessandro https://orcid.org/0000-0001-6896-4509
Ruocco, Giancarlo https://orcid.org/0000-0002-2762-9533
Leonetti, Marco https://orcid.org/0000-0001-7106-0850
Reale, Riccardo https://orcid.org/0000-0002-7697-8895
-
Funding
Funding for this research was provided by:
MTF Biologics (OSTEOMIMIC)
European Research Council (Synergy Grant ASTRA (no. 855923))
Call POR-FESR “Gruppi di Ricerca 2020" (A0375-2020-36549)
MUR PRIN 2022 (2022CFP7RF)
Fondazione Roche per la Ricerca Indipendente (2023)
Istituto Italiano di Tecnologia
- License Information
-
More Information
Article History
Received: 16 December 2024
Accepted: 22 March 2025
First Online: 15 April 2025
Declarations
:
: The authors declare no competing interests.
: Human Bone Marrow Mesenchymal Stem Cells (HBMSCs) were used in accordance with the Declaration of Helsinki and its later amendments and the study was approved by the Institutional Review Board (June 22, 2023 Department of Molecular Medicine, Sapienza University, and September 6, 2023 Ethical Committee of Sapienza University and Policlinico Umberto I, Rome, Italy, approval numbers Rif. 7311—Prot. 0706/2023).
